Search Icon
OTLK Archived Articles

Outlook Therapeutics (OTLK): Navigating the Path to Approval and Commercialization of the First Ophthalmic Bevacizumab

Published on November 30, 2024

Outlook Therapeutics, Inc. (NASDAQ:OTLK): Poised for Potential Approval and Launch in Europe, Advancing Towards U.S. Resubmission

Published on September 24, 2024